Travere Therapeutics to Present at Upcoming Investor Conferences
09 nov. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022...
Travere Therapeutics Reports Third Quarter 2022 Financial Results
27 oct. 2022 16h01 HE
|
Travere Therapeutics, Inc.
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
26 oct. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs,...
Travere Therapeutics to Report Third Quarter 2022 Financial Results
20 oct. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the...
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
13 oct. 2022 16h05 HE
|
Travere Therapeutics, Inc.
Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 oct. 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 sept. 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
25 août 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of...
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
22 août 2022 07h00 HE
|
Travere Therapeutics, Inc.
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 août 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2022, the Compensation Committee of its Board of Directors granted...